Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Instil Bio, Inc. (NQ: TIL )

29.05 +0.61 (+2.14%)
Streaming Delayed Price Updated: 9:30 AM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 690
Open 29.05
Bid (Size) 28.96 (3)
Ask (Size) 29.48 (1)
Prev. Close 28.44
Today's Range 29.05 - 29.05
52wk Range 6.070 - 92.00
Shares Outstanding 3,290,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga

Performance

YTD
+273.87%
+273.87%
1 Month
-18.40%
-18.40%
3 Month
+148.08%
+148.08%
6 Month
+158.68%
+158.68%
1 Year
+287.75%
+287.75%

More News

Read More
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Via The Motley Fool
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
Via InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
Via InvestorPlace
Here's Why Everyone's Talking About Summit Therapeutics
Via The Motley Fool
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
From Instil Bio
Via GlobeNewswire
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
Via InvestorPlace
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Via The Motley Fool
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
Via Talk Markets
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
Via InvestorPlace
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
Via InvestorPlace
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.